. Author manuscript; available in PMC: 2023 Feb 22.

Published in final edited form as: Nat Med. 2022 Dec 7;29(2):376–383. doi: 10.1038/s41591-022-02120-7

Extended Data Table 2.

Primary analysis hypothesis 1. Absolute unadjusted values for HbA1c on pioglitazone and sitagliptin split by BMI strata and the corresponding mean difference between drugs, and between strata. P value assessed by a t test comparing the difference between drugs between strata.

BMI category	Drug	HbA1c (mmol/mol) Mean (SD)	Difference between drugs (mmol/mol) Mean (95% CI)^*	Difference between strata (mmol/mol) (95% CI)	p
BMI<=30 n=141	Pioglitazone	59.7 (10.4)	1.48 (0.04, 2.91)	2.92 (0.99, 4.85)	0.003
BMI<=30 n=141	Sitagliptin	58.3 (8.6)	1.48 (0.04, 2.91)
BMI>30 n=215	Pioglitazone	59.0 (11.5)	-1.44 (-2.70, -0.19)
BMI>30 n=215	Sitagliptin	60.5 (11.2)	-1.44 (-2.70, -0.19)

negative values favour pioglitazone.